Biomarker: M003-IgE Aspergillus fumigatus

Overview

M003-IgE Aspergillus fumigatus measures immunoglobulin E (IgE) antibodies in blood that specifically recognize A. fumigatus antigens. IgE mediates immediate hypersensitivity by binding to mast cells and basophils, where allergen exposure can trigger release of inflammatory mediators. A positive or elevated result indicates sensitization to A. fumigatus, but does not by itself establish symptomatic allergy, allergic bronchopulmonary aspergillosis (ABPA), or invasive aspergillosis. The test is clinically useful as part of the evaluation for Aspergillus-related allergic disease, particularly in patients with asthma, cystic fibrosis, bronchiectasis, or compatible clinical and radiologic findings.

Clinical Use Cases

Assess sensitization to A. fumigatus in patients with suspected ABPA.
Support evaluation of difficult-to-control asthma, cystic fibrosis, bronchiectasis, or other compatible airway disease.
Contribute to ABPA diagnostic assessment alongside total serum IgE, A. fumigatus-specific IgG, eosinophil count, and chest imaging.
Help distinguish A. fumigatus sensitization from nonspecific elevation of total IgE.
Support evaluation of allergic fungal airway disease when clinical findings suggest a reaction to Aspergillus species.
Provide a blood-based alternative when skin-prick testing is unsuitable or unavailable.
Assist longitudinal assessment of sensitization when interpreted with clinical status and other disease markers; it is not a stand-alone disease-activity marker.

Specimen Types

Venous blood.
Serum, typically separated from the collected blood sample.

Measurement Methods

In-vitro allergen-specific IgE immunoassay.
Fluorescence enzyme immunoassay, including ImmunoCAP-type assays.
Enzyme-linked immunosorbent assay (ELISA).
Other validated automated or solid-phase immunoassays.
Results may be reported in kUA/L, kU/L, IU/mL, or an assay-specific class or grade system. Cutoffs and reporting conventions vary by platform.
Skin-prick or immediate hypersensitivity testing measures Aspergillus reactivity by a different method and is not a measurement of serum M003-IgE.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergen-specific IgE blood test.
Tell the healthcare professional about all medications and supplements. Do not stop prescribed medicines unless instructed.
Antihistamines can affect skin-prick testing, but generally do not interfere with blood-based specific-IgE measurement.
Systemic corticosteroids may reduce total IgE or other inflammatory findings and can affect interpretation of an ABPA evaluation; clinical guidelines recommend considering repeat assessment after steroid treatment when appropriate.
The result reflects immune sensitization and should be interpreted with symptoms, asthma or other predisposing disease, total IgE, eosinophil count, A. fumigatus-specific IgG, and imaging.
A positive result does not prove that current symptoms are caused by A. fumigatus. False-positive or clinically irrelevant sensitization can occur, and a negative result does not exclude every form of Aspergillus-related disease.
Assay platforms, allergen extracts, units, reference intervals, and decision thresholds are not fully interchangeable.
For ABPA evaluation, current guidelines commonly use A. fumigatus-specific IgE of at least 0.35 kUA/L as evidence of sensitization, together with other required clinical, immunologic, and radiologic findings.